Results 151 to 160 of about 32,043 (265)
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Brace yourselves, vaccine-preventable diseases are coming! The impact of war on polio and other vaccine-preventable diseases. [PDF]
Costa TG +6 more
europepmc +1 more source
Correction: Vaccine cold chain and understanding what underpins vaccine security for vaccine preventable diseases. [PDF]
europepmc +1 more source
Developing community-based surveillance systems for vaccine-preventable diseases: lessons learned from Indonesia. [PDF]
Sitorukmi G +4 more
europepmc +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Parental vaccine refusal, non-vaccinated children, and outbreaks of Vaccine-Preventable Diseases (VPDs) in Europe: a systematic review of aetiology and risk. [PDF]
Baiocchi C, Bhardwaj M.
europepmc +1 more source
British National Formulary Guidance on prescribing in pregnancy: A descriptive cross‐sectional study
Aim To assess how well pregnancy‐specific guidance within the British National Formulary supports healthcare professionals to facilitate safe and effective medication use. Methods We performed a manifest content analysis of the text of all pregnancy sections within British National Formulary drug monographs, with inductive and iterative coding.
Hannah Johnson +9 more
wiley +1 more source
Abstract Aims Risk minimization measures (RMMs) are key regulatory tools to ensure safe medicinal product use. Regulatory guidelines recommend pre‐specifying the targets, or ‘thresholds’, for assessing RMM effectiveness. We aimed to review recent industry‐sponsored post‐authorization safety studies (PASS) that evaluated the effectiveness of RMMs ...
Kexin Zhu +7 more
wiley +1 more source
ABSTRACT Messenger ribonucleic acid (mRNA) therapeutics produced by in vitro transcription must be purified to remove residual enzymes and free nucleotides. This study examines the use of high‐performance countercurrent membrane purification (HPCMP) for the purification of mRNA therapeutics based on differences in the rate of diffusion across ...
Ziqiao Wang +3 more
wiley +1 more source

